Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-centre, open-label extension trial of treatment with ZD1839 (Iressa) in patients who have been treated in other ZD1839 clinical trials and may benefit from continued monotherapy ZD 1839.

Next Previous
Search
Trial Profile

Multi-centre, open-label extension trial of treatment with ZD1839 (Iressa) in patients who have been treated in other ZD1839 clinical trials and may benefit from continued monotherapy ZD 1839.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca

    • Most Recent Events

    • 01 May 2009 Actual end date changed from 1 Mar 2003 to 1 Oct 2003.
    • 04 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top